CCNT2

Across TCGA pan-cancer cohorts, CCNT2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CCNT2 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CCNT2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CCNT2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and PDAC show a favorable association.

UCEC, PDAC, and GBM are the cancer types where CCNT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.937	0.779	.021	8	view →
PDAC	DFS	Quartile	III,IV	0.882	0.432	.034	4	view →
GBM	OS	Tertile	All	0.481	0.270	.033	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CCNT2–UCEC (DFS)

Open the UCEC breakdown →